1.
|
9 p, 1.2 MB |
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide
/
Fernandez-Perez, María P. (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Perez-Navarro, Enrique (Hospital Universitario 12 de Octubre (Madrid)) ;
Alonso-Gordoa, Teresa (Hospital Universitario Ramón y Cajal (Madrid)) ;
Conteduca, Vincenza (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) "Dino Amadori" IRCCS) ;
Font, Albert (Institut Català d'Oncologia) ;
Vázquez-Estévez, Sergio (H. Universitario Lucus Augusti) ;
González-del-Alba, Aránzazu (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Wetterskog, Daniel (Paul O'Gorman Building) ;
Antonarakis, Emmanuel S. (Johns Hopkins University School of Medicine) ;
Mellado, Begona (Hospital Clínic i Provincial de Barcelona) ;
Fernandez-Calvo, Ovidio (Complejo Hospitalario Universitario Ourense) ;
Méndez-Vidal, María J. (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Climent, Miguel Ángel (Fundació Institut Valencià d'Oncologia) ;
Duran, Ignacio (Instituto de Biomedicina de Sevilla) ;
Gallardo, Enrique (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Rodriguez Sanchez, Angel (Hospital Universitario de León) ;
Santander, Carmen (Hospital Universitario Miguel Servet (Saragossa)) ;
Sáez, Maria I. (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Puente, Javier (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ;
Tudela, Julian (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Martínez, Alberto (Biobanco de la región de Murcia) ;
López-Andreo, Maria J. (SAI-IMIB-Universidad de Murcia) ;
Padilla, José (Hospital Universitario Morales Meseguer) ;
Lozano, Rebeca (Instituto de Investigación Biomédica de Málaga) ;
Hervas, David (Instituto de Investigación Sanitaria La Fe) ;
Luo, Jun (Johns Hopkins University School of Medicine) ;
De Giorgi, Ugo (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) "Dino Amadori" IRCCS) ;
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Attard, Gerhardt (Paul O'Gorman Building) ;
Grande, Enrique (MD Anderson Cancer Center Madrid) ;
Gonzalez-Billalabeitia, Enrique (Universidad Católica San Antonio de Murcia-UCAM) ;
Universitat Autònoma de Barcelona
There is a considerable need to incorporate biomarkers of resistance to new antiandrogen agents in the management of castration-resistant prostate cancer (CRPC). We conducted a phase II trial of enzalutamide in first-line chemo-naïve asymptomatic or minimally symptomatic mCRPC and analyzed the prognostic value of TMPRSS2-ERG and other biomarkers, including circulating tumor cells (CTCs), androgen receptor splice variant (AR-V7) in CTCs and plasma Androgen Receptor copy number gain (AR-gain). [...]
2022 - 10.1002/pros.24469
The Prostate, Vol. 83 (december 2022)
|
|
2.
|
6 p, 1.4 MB |
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
/
Conteduca, Vincenza (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori) ;
Jayaram, Anuradha (University College London Cancer Institute) ;
Romero-Laorden, Nuria (Hospital Universitario de la Princesa (Madrid)) ;
Wetterskog, Daniel (University College London Cancer Institute) ;
Salvi, Samanta (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori) ;
Gurioli, Giorgia (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori) ;
Scarpi, Emanuela (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori) ;
Castro, Elena (Hospital Universitario Quirón, Madrid) ;
Marin-Aguilera, Mercedes (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Lolli, Cristian (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori) ;
Schepisi, Giuseppe (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori) ;
Maugeri, Antonio (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori) ;
Wingate, Anna (University College London Cancer Institute) ;
Farolfi, Alberto (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori) ;
Casadio, Valentina (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori) ;
Medina, Ana (Centro Oncológico de Galicia) ;
Puente, Javier (Instituto de Investigación Sanitaria del Hospital Clínico San Carlos) ;
Vidal, Mª José Méndez (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Morales-Barrera, Rafael (Vall d'Hebron Institut d'Oncologia) ;
Villa-Guzmán, Jose C. (Hospital General Universitario de Ciudad Real) ;
Hernando, Susana (Hospital Universitario Fundación Alcorcón) ;
Rodriguez-Vida, Alejo (Hospital del Mar (Barcelona, Catalunya)) ;
González-del-Alba, Aránzazu (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Mellado, Begoña (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Gonzalez-Billalabeitia, Enrique (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Olmos, David (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Attard, Gerhardt (University College London Cancer Institute) ;
De Giorgi, Ugo (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori) ;
Universitat Autònoma de Barcelona
Plasma androgen receptor (AR) gain identifies metastatic castration-resistant prostate cancer (mCRPC) patients with worse outcome on abiraterone/enzalutamide, but its relevance in the context of taxane chemotherapy is unknown. [...]
2019 - 10.1016/j.eururo.2018.09.049
European Urology, Vol. 75 (march 2019) , p. 368-373
|
|
3.
|
9 p, 341.6 KB |
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
/
Conteduca, Vincenza (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Wetterskog, Daniel (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Sharabiani, M. T. A. (Royal Marsden NHS Foundation Trust. Research Data Management and Statistics Unit) ;
Grande, Enrique (Hospital Universitario Ramón y Cajal (Madrid)) ;
Fernandez Perez, M. P. (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Jayaram, Anuradha (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Salvi, S. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ;
Romanel, A. (Università di Trento. Centro di Biologia Integrata) ;
Lolli, C. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Casadio, Valentina (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Gurioli, Giorgia (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Amadori, D. (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Font Guiteras, Antoni (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Vazquez Estevez, S. (Hospital Universitario Lucus Augusti (Lugo)) ;
González-del-Alba, Aránzazu (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Mellado, B. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Fernandez Calvo, O. (Complejo Hospitalario Universitario de Ourense) ;
Méndez Vidal, M. J. (Hospital Universitario Reina Sofía (Còrdova, Espanya)) ;
Climent, Miguel Ángel (Fundació Institut Valencià d'Oncologia) ;
Durán, Ignacio (Instituto de Biomedicina de Sevilla) ;
Gallardo, Eduard (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Rodríguez Sánchez, Ángel (Hospital Universitario de León) ;
Santander, C. (Hospital Universitario Miguel Servet (Saragossa)) ;
Sáez, M. I. (Hospital Regional Universitario de Málaga) ;
Puente, J. (Hospital Clínico San Carlos (Madrid)) ;
Gasi Tandefelt, D. (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Wingate, Anna (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Dearnaley, David (Royal Marsden NHS Foundation Trust. Academic Urology Unit) ;
Demichelis, F. (Università di Trento. Centro di Biologia Integrata) ;
De Giorgi, Ugo (Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS) ;
Gonzalez-Billalabeitia, Enrique (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Attard, Gerhardt (Centre for Evolution and Cancer. The Institute of Cancer Research, London) ;
Spanish Oncology Genitourinary Group ;
Universitat Autònoma de Barcelona
Background: There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex droplet digital PCR (ddPCR) in pre- and post-chemotherapy CRPC. [...]
2017
Annals of oncology, Núm. 28 (2017) , p. 1508-1516
|
|